Former GlaxoSmithKline exec reportedly in line to be White House 'therapeutics czar'

Maia Anderson - Print  | 

The former head of GlaxoSmithKline's vaccine division, Moncef Slaoui, PhD, will serve as the government's therapeutics czar, a role designed to help speed the development of potential COVID-19 vaccines, Politico reported. 

Dr. Slaoui left GlaxoSmithKline in 2017 and has worked as a venture capitalist since. In his role as therapeutics czar, he will help coordinate the development of COVID-19 vaccines and treatments. 

The position is part of a program the White House calls Operation Warp Speed, designed to drastically cut the time needed to develop a COVID-19 vaccine. 

Dr. Slaoui also sits on the board of Moderna, a drugmaker developing a COVID-19 vaccine, Politico reported. His role as therapeutics czar will be split between HHS and the U.S. Defense Department. 

Read the full article here.

More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.